Metraipolis › archive › dc_d6cf2b4dc606
Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic… — Europe PMC PMID:41278271
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41278271
- DOI
- 10.3389/fonc.2025.1624286
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T18:35:34.257Z
- SHA-256 of the archived text
c9ba09a32580e709492180a7cbf165819196b45d3c32d9bd9b0c73b7be06e1c2- Stable URL of this page
https://metraipolis.com/documento/dc_d6cf2b4dc606
How to cite
Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic… — Europe PMC PMID:41278271 — Europe PMC (en), https://europepmc.org/article/MED/41278271 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d6cf2b4dc606 (Metraipolis archive dc_d6cf2b4dc606, sha256 c9ba09a32580e709492180a7cbf165819196b45d3c32d9bd9b0c73b7be06e1c2)
BibTeX
@misc{dcd6cf2b4dc606,
title = {Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic… — Europe PMC PMID:41278271},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41278271},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d6cf2b4dc606; sha256 c9ba09a32580e709492180a7cbf165819196b45d3c32d9bd9b0c73b7be06e1c2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41278271. Agents can read the archived copy with the MCP tool read_document.